The Drug-Induced Respiratory Disease Website and App

Frequency - Incidence

Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases

Evidence level/grade

Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic

LIX.x

Cryptococcus pulmonary and/or systemic infection

Publications

Yamada S, Kajihara I, Johno T, Fukushima S, Jinnin M, Masunaga A, Kohrogi H, Ihn H

Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy.

Annals of dermatology 2016 Apr;28;269-70 — 2016 Apr — 269-70

Takazono T, Izumikawa K, Yoshioka S, Matsuo N, Yamakawa M, Suyama N, Kohno S

Possible pulmonary cryptococcosis in a patient with Crohn's disease during anti-tumor necrosis factor-alpha treatment: a case report and literature review.

Japanese journal of infectious diseases 2012;65;461-4 — 2012 — 461-4

Hirai F, Matsui T, Ishibashi Y, Higashi D, Futami K, Haraoka S, Iwashita A

Asymptomatic pulmonary cryptococcosis in a patient with Crohn's disease on infliximab: case report.

Inflammatory bowel diseases 2011 Jul;17;1637-8 — 2011 Jul — 1637-8